a plus sign (+) inside this box -> +

6,018,024

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent No. 6,018,026

Issued: January 25, 2000

Andrzej Z. Sledziewski

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

byder the Paperwork Reduction Art of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Group Art Unit

Filing Date

Application Number

First Named Inventor

Examiner Name L. Spector

Total Number of Pages	1	Attorn	ey Docket Number	13952A-005321US		
		ENCLO	SURES	(check all that apply)		
Fee Transmittal Form		Assignment Papers (for an Application)			After Allowance Communication to Group	
Fee Attached		Drawing(s)			Appeal Communication to Board of Appeals and Interferences	
Amendment / Response		Licensing-related Papers			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final		Petition Routing Slip (PTO/SB/69) and Accompanying Petition			Proprietary Information	
Affidavits/declaration(s)		Petition to Convert to a Provisional Application			Status Letter	
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address			Other Enclosure(s) (please identify below):	
Express Abandonment Request		☐ Terminal Disclaimer ☐ Request for Refund			Request for Certificate of Correction; Certificate of Correction; Return Postcard	
☐ Information Disclosure Statement		CD, Number of CD(s)		CD(s)		
Certified Copy of Priority Document(s)		Rema	The Commissioner is authorized to charge any additional fees Deposit Account 20-1430.		30. 📆	
					CERTIFICATE	
Response to Missing Parts/ Incomplete Application		APR 1 1 2002				
Response to Missing						
Parts under 37 CFR 1.52 or 1.53		OF CORRECTION				
	SIGNA	TURE OF	APPLIC	ANT. ATTORNEY. OI		
Firm	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Townsend and Townsend and Crew LLP					
and Individual name	Mark G. Sandbaken, Ph.D. Reg. No.				. 39,354	
Signature	M Sol-					
Date 03-25-02						

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal S	ervice with sufficient postage as first
class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington,	D.C. 20231 on this date:
,	03-25-02

Jennifer M. Smolen Typed or printed name

Signature

03-25-02

Burden Hour Statement: This form\is estimated-to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SE 5012326 v1



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Asst. Comprissioner of Patents and Trademarks, Washington, D.C. on

By: White

<u>PATENT</u> 13952A-005321US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the patent of:

ANDRZEJ Z. SLEDZIEWSKI et al.

Examiner:

L. Spector

Patent No.: 6,018,026

Issued: January 25, 2000

For: BIOLOGICALLY ACTIVE

DIMERIZED AND

MULTIMERIZED POLYPEPTIDE

FUSIONS

REQUEST FOR CERTIFICATE OF CORRECTION

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 CFR § 1.322, Applicants submit a Certificate of Correction correcting an error made at the time of printing of the patent. The desired correction is set forth on form PTO-1050 enclosed.

The error for which correction is requested is the deletion of the word "heavy" in the last line (col. 100, line 42) of issued claim 12, and the insertion of the word "light" therefore. Issued claim 12 was claim 39 during prosecution.

The error is readily apparent from the prosecution history. In the Examiner's amendment accompanying the Notice of Allowability (Paper No. 12), the Examiner indicated that claim 39 would be amended at line 5 to replace "light" with "heavy." This amendment was intended to change the phrase "joined to an immunoglobulin *light* chain constant region; and an immunoglobulin light chain" to the phrase "joined to an immunoglobulin *heavy* chain constant region; and an immunoglobulin light chain" (emphasis added). (See Paper No. 7, Amendment filed March 29, 1999, page 3, for line numbering.) In claim 12 of the issued patent, both instances of the word "light" were changed to "heavy." Claim 12 should read,

ANDRZEJ Z. SLEDZIEWSKI et al.

Patent No.: 6,018,026

Page 2

inter alia, "joined to an immunoglobulin heavy chain constant region; and an immunoglobulin light chain" (emphasis added). Correction of this error is respectfully requested.

This error is not due to the fault of Applicants. Please charge (or credit) any fees associated with this request to the firm's Deposit Account No. 20-1430.

Respectfully submitted,

Dated: 3/25/02

By: Merla C. Sandhalan

Mark G. Sandbaken Reg. No. 39,354

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Telephone: (206) 467-9600

Fax: (415) 576-0300

MGS/acg SE 5011090 v1